Substance / Medication

Modafinil

Overview

Active Ingredient
modafinil
RxNorm CUI
30125

Indications

Modafinil tablets are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). Limitations of Use In OSA, modafinil tablets are indicated to treat excessive sleepiness and not as treatment for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made

Labeler: Aphena Pharma Solutions - Tennessee, LLCUpdated: 2026-02-12T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

5.1 5.2 5.3 [see Warnings and Precautions (,,)] Modafinil is contraindicated in patients with known hypersensitivity to modafinil or armodafinil or its inactive ingredients.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Research Evidence

Published studies and systematic reviews

Sort:
Assessing Condition-Specific Adverse Event Profiles of Modafinil for Labelled and Off-Label Uses: A Systematic Review and Meta-Analysis.
Jung Jaehee, Youm Jaeyoon, Kang Jihyun et al. · Basic Clin Pharmacol Toxicol · 2026
PMID: 41367108Meta-AnalysisFull text (PMC)
Modafinil/armodafinil for excessive daytime sleepiness after traumatic brain injury: a systematic review and meta-analysis.
João Rafael Batista, Pacheco-Barrios Niels, Leite Marianna et al. · Brain Inj · 2025
PMID: 40388311Meta-Analysis
Repurposing of modafinil as an anti-inflammatory drug: a systematic review of experimental studies.
Amini Mohammad Javad, Seighali Niloofar, Arabazadeh Bahri Razman et al. · Naunyn Schmiedebergs Arch Pharmacol · 2025
PMID: 40358683Meta-Analysis
The use of modafinil for the treatment of fatigue in multiple sclerosis: A systematic review and meta-analysis of controlled clinical trials.
Ghazanfar Shamas, Farooq Minaam, Qazi Shurjeel Uddin et al. · Brain Behav · 2024
PMID: 38988104Meta-AnalysisFull text (PMC)
Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea.
Ronnebaum Sarah, Bron Morgan, Patel Dipen et al. · J Clin Sleep Med · 2021
PMID: 34402784Meta-AnalysisFull text (PMC)
Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: A meta-analysis of randomized controlled trials.
Nunez Nicolas A, Singh Balwinder, Romo-Nava Francisco et al. · Bipolar Disord · 2020
PMID: 31643130Meta-Analysis
Amantadine and Modafinil as Neurostimulants During Post-stroke Care: A Systematic Review.
Gagnon David J, Leclerc Angela M, Riker Richard R et al. · Neurocrit Care · 2020
PMID: 32394130Meta-Analysis
Modafinil for poststroke patients: A systematic review.
Pacheco Rafael Leite, Latorraca Carolina de Oliveira Cruz, da Silva Luciana Di Giovanni Marques et al. · Int J Clin Pract · 2019
PMID: 30444561Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Modafinil (substance)
SNOMED CT
387004007
UMLS CUI
C0066677
RxNorm CUI
30125
Labeler
Aphena Pharma Solutions - Tennessee, LLC

Clinical Data

This intervention maps to 9 entities in the Healos knowledge graph.

3
Conditions
2
Biomarkers
3
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.